对针对骨髓瘤的向免疫疗法的图书统计分析:目前的知识,热点和未来的前景
Yunxiang Hu1,2, Rui Yang2, Shuai Ni1,2
1Department of Orthopaedic Trauma, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Frontiers in immunology
|February 25, 2025
概括
本文献分析回顾了2000年至2023年的骨髓瘤免疫疗法 (ITFOS) 研究. 关键趋势包括免疫微环境和预后特征,突出中国.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 图书统计学 图书统计学
背景情况:
- 骨肉瘤仍然是儿科和年轻成人瘤学的重大挑战.
- 免疫疗法为新的治疗策略提供了一个有希望的途径.
- 了解研究趋势对于推进ITFOS至关重要.
研究的目的:
- 进行骨髓瘤免疫疗法 (ITFOS) 研究的文献分析.
- 确定ITFOS当前的研究状况,关键领域和新兴趋势.
- 评估全球研究格局和ITFOS的合作努力.
主要方法:
- 从科学网络 (2000-2023) 出版物的图书统计分析.
- 使用的工具:HisCite,VOSviewer,CiteSpace和文献计量工具包.
- 分析的数据包括国家,机构,作者,期刊和关键词.
主要成果:
- 来自43个国家的3725位作者在247个期刊上发表了616篇论文.
- 中国在出版 (44.99%) 方面处于领先地位;江大学和图莫希德·图卡哈拉是最具生产力的.
- 免疫学的边界是最富有成效的期刊",骨肉瘤"",免疫疗法"和"癌症"是常见的关键词.
结论:
- ITFOS的研究正在迅速发展,中国的贡献很大.
- 新兴的研究领域包括"测序"",预后签名"和"免疫微环境".
- 该研究强调了国际合作在推进ITFOS研究方面的重要性.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


